Intellia (NTLA) | Financial Analysis & Statements
Intellia Therapeutics Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
23.0M
Operating Income
-98.7M
-428.86%
Net Income
-95.8M
-416.15%
EPS (Diluted)
$-0.83
Balance Sheet Metrics
Total Assets
842.1M
Total Liabilities
170.7M
Shareholders Equity
671.4M
Debt to Equity
0.25
Cash Flow Metrics
Operating Cash Flow
-72.9M
Free Cash Flow
-69.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Intellia Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 67.7M | 57.9M | 36.3M | 52.1M | 33.1M |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 388.9M | 466.3M | 435.1M | 420.0M | 229.8M |
| Selling, General & Administrative | 119.8M | 125.8M | 116.5M | 90.3M | 71.1M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 508.7M | 592.1M | 551.6M | 510.3M | 300.9M |
| Operating Income | -441.0M | -534.3M | -515.3M | -458.2M | -267.8M |
| Operating Margin % | -651.7% | -923.1% | -1,420.5% | -879.0% | -810.4% |
| Non-Operating Items | |||||
| Interest Income | 29.2M | 47.8M | 49.8M | 8.5M | 1.3M |
| Interest Expense | - | - | - | - | - |
| Other Non-Operating Income | -899.0K | -32.6M | -15.7M | -24.6M | -1.3M |
| Pre-tax Income | -412.7M | -519.0M | -481.2M | -474.2M | -267.9M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -412.7M | -519.0M | -481.2M | -474.2M | -267.9M |
| Net Margin % | -609.9% | -896.8% | -1,326.5% | -909.8% | -810.5% |
| Key Metrics | |||||
| EBITDA | -424.2M | -491.4M | -506.2M | -437.1M | -261.0M |
| EPS (Basic) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| EPS (Diluted) | $-3.81 | $-5.25 | $-5.42 | $-6.16 | $-3.78 |
| Basic Shares Outstanding | 108376000 | 98849000 | 88770000 | 76972000 | 70894000 |
| Diluted Shares Outstanding | 108376000 | 98849000 | 88770000 | 76972000 | 70894000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Intellia Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 155.5M | 189.2M | 226.7M | 523.5M | 123.4M |
| Short-term Investments | 294.4M | 412.3M | 685.5M | 669.1M | 625.3M |
| Accounts Receivable | 9.5M | 8.5M | 36.5M | 3.8M | 2.0M |
| Inventory | - | - | - | - | - |
| Other Current Assets | 68.4M | 29.8M | 49.7M | 20.4M | 18.6M |
| Total Current Assets | 527.7M | 639.9M | 998.3M | 1.2B | 769.3M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 173.8M | 287.6M | 179.3M | 185.0M | 119.0M |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 314.4M | 551.2M | 302.6M | 303.3M | 525.2M |
| Total Assets | 842.1M | 1.2B | 1.3B | 1.5B | 1.3B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 20.3M | 14.6M | 7.5M | 5.2M | 9.7M |
| Short-term Debt | 26.5M | 20.2M | 18.6M | 16.7M | 9.1M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 103.9M | 110.9M | 115.2M | 126.6M | 125.8M |
| Non-Current Liabilities | |||||
| Long-term Debt | 66.8M | 190.0M | 96.7M | 114.0M | 64.9M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | 24.0M | - |
| Total Non-Current Liabilities | 66.8M | 208.2M | 135.6M | 158.0M | 128.4M |
| Total Liabilities | 170.7M | 319.1M | 250.8M | 284.5M | 254.2M |
| Equity | |||||
| Common Stock | 12.0K | 10.0K | 9.0K | 9.0K | 7.0K |
| Retained Earnings | -2.6B | -2.2B | -1.7B | -1.2B | -703.0M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 671.4M | 872.0M | 1.1B | 1.2B | 1.0B |
| Key Metrics | |||||
| Total Debt | 93.3M | 210.2M | 115.3M | 130.7M | 74.0M |
| Working Capital | 423.8M | 529.0M | 883.1M | 1.1B | 643.5M |
Balance Sheet Composition
Intellia Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -412.7M | -519.0M | -481.2M | -474.2M | -267.9M |
| Depreciation & Amortization | 15.9M | 10.3M | 9.0M | 7.6M | 6.9M |
| Stock-Based Compensation | 80.2M | 154.3M | 134.0M | 91.4M | 47.0M |
| Working Capital Changes | -42.1M | 17.1M | -31.3M | -67.6M | -30.4M |
| Operating Cash Flow | -358.7M | -358.4M | -362.8M | -362.0M | -241.4M |
| Investing Activities | |||||
| Capital Expenditures | -1.1M | -5.8M | -14.0M | -13.4M | -12.8M |
| Acquisitions | - | - | 0 | 0 | -3.0M |
| Investment Purchases | -322.5M | -935.6M | -904.5M | -429.0M | -1.0B |
| Investment Sales | 551.7M | 1.1B | 887.1M | 647.6M | 485.6M |
| Investing Cash Flow | 228.0M | 125.6M | -31.3M | 205.1M | -550.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 128.2M | 176.9M | 119.8M | 565.8M | 693.6M |
| Free Cash Flow | -395.9M | -354.7M | -408.1M | -391.7M | -237.8M |
| Net Change in Cash | -2.5M | -55.9M | -274.3M | 409.0M | -98.6M |
Cash Flow Trend
Intellia Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-3.54
Forward P/E
-4.62
Price to Book
2.34
Price to Sales
23.55
PEG Ratio
0.10
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-428.86%
Return on Equity
-53.48%
Return on Assets
-27.11%
Financial Health
Current Ratio
5.08
Debt to Equity
13.90
Beta
1.99
Per Share Data
EPS (TTM)
$-3.81
Book Value per Share
$5.77
Revenue per Share
$0.62
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| NTLA | 1.6B | -3.54 | 2.34 | -53.48% | 0.00% | 13.90 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adaptive | 2.1B | -35.44 | 9.99 | -27.82% | -21.48% | 93.49 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Agios | 1.5B | 3.82 | 1.26 | -30.20% | 88.26% | 3.37 |
Financial data is updated regularly. All figures are in the company's reporting currency.






